Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an update.
Shanghai Haohai Biological Technology Co., Ltd. reported a slight increase in revenue for the year ended December 31, 2024, reaching RMB2,679.67 million, a 1.7% rise from the previous year. The company’s R&D expenses also increased by 8.56%, maintaining a high percentage of revenue. Despite these increases, net profit remained flat compared to 2023. The board proposed a reduced final dividend of RMB0.60 per share, down from RMB1.00 in 2023, reflecting a cautious approach to shareholder returns.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in China, focusing on the biotechnology industry. It specializes in developing and providing biological products and services, with a strong emphasis on research and development.
YTD Price Performance: 8.44%
Average Trading Volume: 465,565
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$13.97B
Find detailed analytics on 6826 stock on TipRanks’ Stock Analysis page.